MASTERPLAN is the first randomised trial of stereotactic body radiotherapy (SBRT) in localised pancreatic cancer — and the first to show that adding radiotherapy to modern chemotherapy improves local control. Published in The Lancet Oncology in October 2026 and presented at ESMO 2026, it randomised patients with high-risk localised pancreatic ductal adenocarcinoma to chemotherapy with or without SBRT.
The trial at a glance
74
patients randomised (49 SBRT + chemotherapy, 25 chemotherapy alone)
14
hospitals, Australia and New Zealand (AGITG / GI Cancer Trials)
40 Gy / 5 fractions
SBRT dose; fiducial-guided, TROG real-time quality assurance
2:1
randomisation — chemotherapy ± SBRT
- Who: previously untreated localised PDAC, ECOG 0–1, with at least one high-risk feature
- High-risk features: tumour >4 cm · extrapancreatic extension · node-positive · borderline resectable · locally advanced
- Chemotherapy: investigator choice — modified FOLFIRINOX, or gemcitabine + nab-paclitaxel
- SBRT timing: after 12 weeks of induction chemotherapy (started 4–6 weeks later), delivered over two weeks
- Population mix: potentially operable and inoperable patients both included; resection considered after induction in the operable group
- Primary endpoint: locoregional recurrence at 12 months
Results
20.2% vs 52.0%
locoregional recurrence at 12 months (HR 0.44; p=0.022)
11.9 vs 6.3 mo
median progression-free survival (HR 0.44; p=0.002)
22.0 vs 14.0 mo
median overall survival (HR 0.45; p=0.006)
39% vs 12%
objective radiological response rate
- Toxicity: grade ≥3 adverse events 70% (SBRT) vs 64% (chemotherapy alone), p=0.27 — no significant increase
- Only 1 grade ≥3 event was attributed to the SBRT itself
- Delivery: 80% of patients assigned to SBRT actually started it (39 of 49); results are intention-to-treat
- Median follow-up: 3.2 years
Why earlier trials didn’t show this
- LAP07: conventional chemoradiation after gemcitabine-based induction — no survival benefit
- Alliance A021501: hypofractionated radiotherapy added to mFOLFIRINOX in borderline resectable disease — the radiotherapy arm fared worse
- MASTERPLAN differs: true SBRT (40 Gy in 5 fractions), fiducial guidance, central real-time RT quality assurance, and contemporary chemotherapy
What it means, and what it doesn’t prove
What it supports:
- First randomised evidence that SBRT improves locoregional control and progression-free survival in localised PDAC
- For borderline resectable or locally advanced patients who have not progressed on induction chemotherapy, SBRT now has trial evidence behind it in the multidisciplinary discussion
- 40 Gy in 5 fractions, delivered with fiducials and rigorous QA, added no measurable severe toxicity to modern chemotherapy
What it doesn’t prove:
- A survival benefit — overall survival was a secondary endpoint; the trial closed early (74 of a planned 120 patients, slow accrual) and was underpowered for survival
- Who benefits most — operable and inoperable patients were pooled, so the neoadjuvant and definitive questions cannot yet be separated
- The optimal technique — dose escalation, MR-guidance and adaptive radiotherapy were not tested here (NRG-GI011 / LAP100 is addressing dose escalation)
Bottom line: SBRT in high-risk localised pancreatic cancer moves from “reasonable in selected patients” to “supported by randomised evidence for local control” — with a survival signal that a phase III trial now needs to confirm.
References
- Oar A, Kneebone A, Sjoquist KM, et al. Perioperative chemotherapy and stereotactic body radiotherapy versus chemotherapy alone in high-risk localised pancreatic cancer (MASTERPLAN): a randomised phase 2 trial. Lancet Oncol 2026. doi:10.1016/S1470-2045(26)00532-2
- Trial registrations: ACTRN12619000409178; ClinicalTrials.gov NCT04089150.